Driven by the hypothesis that the benefits of vitamin D in patients is likely to be critically influenced by the molecular subtype of LUAD, in the current study we aim to investigate the prognostic value of vitamin D status in EGFR-mutant and KRAS-mutant NSCLC, as well as its activity in EGFR mutant LUAD cells (a candidate responsive subset). Here, KRAS is linked to non-small cell lung carcinoma.